Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Receivables - Other (2023 - 2025)

Historic Receivables - Other for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $699000.0.

  • BioLineRx's Receivables - Other rose 9971.43% to $699000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $699000.0, marking a year-over-year increase of 9971.43%. This contributed to the annual value of $1.5 million for FY2024, which is 7807.23% up from last year.
  • BioLineRx's Receivables - Other amounted to $699000.0 in Q3 2025, which was up 9971.43% from $203000.0 recorded in Q2 2025.
  • In the past 5 years, BioLineRx's Receivables - Other registered a high of $1.5 million during Q4 2024, and its lowest value of $128000.0 during Q2 2023.
  • Moreover, its 3-year median value for Receivables - Other was $452000.0 (2025), whereas its average is $538181.8.
  • As far as peak fluctuations go, BioLineRx's Receivables - Other surged by 41250.0% in 2024, and later plummeted by 6905.49% in 2025.
  • Quarter analysis of 3 years shows BioLineRx's Receivables - Other stood at $830000.0 in 2023, then surged by 78.07% to $1.5 million in 2024, then tumbled by 52.71% to $699000.0 in 2025.
  • Its Receivables - Other stands at $699000.0 for Q3 2025, versus $203000.0 for Q2 2025 and $452000.0 for Q1 2025.